Agenus (Nasdaq:AGEN) - Cotización, noticias y análisis

Resumen de acción AGEN

Agenus Inc, empresa biotecnológica en fase clínica, descubre y desarrolla productos inmuno-oncológicos en Estados Unidos y a escala internacional.

Acerca de la empresa

AGEN fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Recompensas

Cotiza un 98.6% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 20.87%

Análisis de riesgos

Patrimonio neto negativo

Alta volatilidad del precio de la acción en los últimos 3 meses

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

+ 1 riesgos adicionales

Competidores de Agenus Inc.

YS Biopharma

NasdaqCM:YS

US$150.7m

CervoMed

NasdaqCM:CRVO

US$196.6m

bluebird bio

NasdaqGS:BLUE

US$177.9m

Rigel Pharmaceuticals

NasdaqGS:RIGL

US$192.9m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Agenus
Historical stock prices
Current Share Price	US$11.69
52 Week High	US$42.60
52 Week Low	US$4.78
Beta	1.28
1 Month Change	5.05%
3 Month Change	-11.79%
1 Year Change	-61.29%
3 Year Change	-81.08%
5 Year Change	-78.43%
Change since IPO	-99.84%

Noticias y actualizaciones recientes

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29

Recent updates

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11

FDA accepts Agenus' balstilimab BLA under "priority review" status

Jun 17

Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy

May 26

Agenus shares fall after Q1 topline miss

May 06

Rentabilidad de los accionistas

	AGEN	US Biotechs	Mercado US
7D	120.2%	-0.2%	2.9%
1Y	-61.3%	-1.0%	22.2%

Rentabilidad vs. Industria: AGEN obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 0.7%.

Rentabilidad vs. Mercado: AGEN obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is AGEN's price volatile compared to industry and market?
AGEN volatility
AGEN Average Weekly Movement	21.6%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de AGEN ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de AGEN ha aumentado de 13% a 18% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1994	389	Garo Armen	www.agenusbio.com

Agenus Inc, empresa de biotecnología en fase clínica, descubre y desarrolla productos inmuno-oncológicos en Estados Unidos y a escala internacional. La empresa ofrece Retrocyte Display, una plataforma de expresión de anticuerpos para la identificación de anticuerpos monoclonales totalmente humanos y humanizados; y tecnologías de visualización. Desarrolla el adyuvante QS-21 Stimulon, un adyuvante para vacunas a base de saponina.

Resumen de fundamentos de Agenus Inc.

¿Cómo se comparan los beneficios e ingresos de Agenus con su capitalización de mercado?
Estadísticas fundamentales de AGEN
Capitalización bursátil	US$245.43m
Beneficios(TTM)	-US$245.97m
Ingresos (TTM)	US$156.31m

1.6x

Ratio precio-ventas (PS)

-1.0x

Ratio precio-beneficio (PE)

¿Está AGEN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de AGEN
Ingresos	US$156.31m
Coste de los ingresos	US$237.68m
Beneficio bruto	-US$81.37m
Otros gastos	US$164.61m
Beneficios	-US$245.97m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 07, 2024

Beneficios por acción (BPA)	-11.72
Margen bruto	-52.05%
Margen de beneficio neto	-157.36%
Ratio deuda/patrimonio	-8.7%

¿Cómo se ha desempeñado AGEN a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción AGEN

Recompensas

Análisis de riesgos

Competidores de Agenus Inc.

NasdaqCM:YS

US$150.7m

NasdaqCM:CRVO

US$196.6m

NasdaqGS:BLUE

US$177.9m

NasdaqGS:RIGL

US$192.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Agenus Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Share price stability

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Consensus revenue estimates increase by 30%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Agenus Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Share price stability

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Consensus revenue estimates increase by 30%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Agenus Inc. to Report Q4, 2023 Results on Mar 14, 2024

Founder recently bought US$324k worth of stock

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 17% to US$6.67

Agenus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas

Now 22% undervalued after recent price drop

Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Agenus Inc. Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Inc. to Report Q2, 2023 Results on Aug 08, 2023

Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Agenus Inc. Announces the Resignation of Wadih Jordan as Director, Effective December 31, 2022

Price target decreased to US$6.33

Insufficient new directors

Agenus Inc. Data At SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Agenus Inc. Announces GSK Disclose Positive Pivotal Phase III Trial Results for Its Respiratory Syncytial Virus Vaccine Candidate

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Investor sentiment improved over the past week

Price target decreased to US$6.33

Agenus New Trials Set It Up For The Long Haul

Investor sentiment deteriorated over the past week

Agenus: It's Always Tomorrow

Agenus Initiates Botensilimab Phase 2 Activate Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Agenus GAAP EPS of -$0.17, revenue of $20.93M

Agenus Inc. Announces First Patient Dosed in Phase 1 Study of AGEN1571 (Anti-ILT2) in Advanced Solid Tumors

Agenus Inc. to Report Q2, 2022 Results on Aug 09, 2022

Agenus: Successfully Pulled Itself Away From Disaster

Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress

Agenus Inc. Announces Positive Headline Results from A Pre-Specified Efficacy Interim Analysis of the Aresvi 006 Phase III Trial Evaluating Their Investigational RSV Vaccine in Adults Aged 60 Years and Above

Price target decreased to US$7.50

Consensus estimates of losses per share improve by 21%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Agenus Inc., Annual General Meeting, Jun 08, 2022

Insufficient new directors

Agenus: Not Quite Enough